211 related articles for article (PubMed ID: 34377229)
21. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).
Ling X; Li F
Am J Transl Res; 2013; 5(2):139-54. PubMed ID: 23573360
[TBL] [Abstract][Full Text] [Related]
22. [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
Mazurenko NN; Gagarin IM; Tsyganova IV; Mochal'nikova VV; Breder VV
Vopr Onkol; 2013; 59(6):751-5. PubMed ID: 24624786
[TBL] [Abstract][Full Text] [Related]
23. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
24. Not all mutations of
Li W; Liu Y; Cai S; Yang C; Lin Z; Zhou L; Liu L; Cheng X; Zeng W
Int J Clin Exp Pathol; 2019; 12(3):957-967. PubMed ID: 31933906
[TBL] [Abstract][Full Text] [Related]
25. KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
Kumar SS; Price TJ; Mohyieldin O; Borg M; Townsend A; Hardingham JE
Gastrointest Cancer Res; 2014 Jan; 7(1):23-6. PubMed ID: 24558511
[TBL] [Abstract][Full Text] [Related]
26. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y
Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546
[TBL] [Abstract][Full Text] [Related]
27. Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.
Ottaiano A; Normanno N; Facchini S; Cassata A; Nappi A; Romano C; Silvestro L; De Stefano A; Rachiglio AM; Roma C; Maiello MR; Scala S; Delrio P; Tatangelo F; Di Mauro A; Botti G; Avallone A; Nasti G
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708575
[TBL] [Abstract][Full Text] [Related]
28. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.
Khan S; Cameron S; Blaschke M; Moriconi F; Naz N; Amanzada A; Ramadori G; Malik IA
World J Gastroenterol; 2014 Mar; 20(11):2979-94. PubMed ID: 24659889
[TBL] [Abstract][Full Text] [Related]
29. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
[TBL] [Abstract][Full Text] [Related]
30. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
31. Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.
Calderon-Aparicio A; Cornejo A; Orue A; Rieber M
Ecancermedicalscience; 2019; 13():890. PubMed ID: 30792807
[TBL] [Abstract][Full Text] [Related]
32. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
[TBL] [Abstract][Full Text] [Related]
33. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
34. Omega-3 fatty acid DHA modulates p53, survivin, and microRNA-16-1 expression in KRAS-mutant colorectal cancer stem-like cells.
Sam MR; Tavakoli-Mehr M; Safaralizadeh R
Genes Nutr; 2018; 13():8. PubMed ID: 29619114
[TBL] [Abstract][Full Text] [Related]
35. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
[TBL] [Abstract][Full Text] [Related]
36. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
37. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
38. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
[TBL] [Abstract][Full Text] [Related]
39. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.
Chen CC; Er TK; Liu YY; Hwang JK; Barrio MJ; Rodrigo M; Garcia-Toro E; Herreros-Villanueva M
PLoS One; 2013; 8(2):e55793. PubMed ID: 23437064
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
